Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
$3.91M
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
20.00
Edison, NJ
Feb 07, 2014
-0.11
$-6.41
2.17
5.62
-25,850.35%
-0.14
-0.00
1.14
36.92
5.62
-471.96%
-328.66%
Similar stocks (5)
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
Enveric Biosciences, Inc.
ENVB
CohBar, Inc.
CWBR
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (5)
Elevation Oncology, Inc.
ELEV
Ocean Biomedical, Inc.
OCEA
Enveric Biosciences, Inc.
ENVB
CohBar, Inc.
CWBR
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%